Abiomed, which specializes in cardiovascular devices, will work as a standalone business as part of J&J’s MedTech operations, according to a Nov. 1 J&J news release.
Both boards of directors approved the acquisition, which J&J said would expand its portfolio of heart failure devices.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.